Clinical trials: Interferon Alpha
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04379518
- Testing
- Recombinant Interferon Alfa-2b, Rintatolimod
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Chronic Hepatitis C
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro compared with interferon alfa-2a or alfa-2b.
- Trial name
- NCT00211692
- Testing
- consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin
- Volunteers
- 64 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Melanoma
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
The goal of this clinical research study is to learn if temozolomide alone or given with pegylated interferon alpha-2b can help to control metastatic melanoma. Researchers also want to study the safety of these 2 treatments.
- Trial name
- NCT00525031
- Testing
- Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
HIV Infection, Hepatitis C
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons…
- Trial name
- NCT01285050
- Testing
- Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Melanoma (Skin)
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006237
- Testing
- interleukin-2, filgrastim, interferon alfa
- Where
- 297 sites in United States, Australia
- Volunteers
- 432 people
- Sponsor
- SWOG Cancer Research Network
Behcet Syndrome, Behcet Disease
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).
- Conditions
- Behcet Syndrome, Behcet Disease, Mucocutaneous Ulceration
- Trial name
- NCT00483184
- Testing
- Veldona,
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Nobel Pharmaceuticals
Upper Respiratory Tract Infections
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu.
- Trial name
- NCT00895947
- Testing
- interferon-alpha
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Hepatitis C, Chronic
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
This is an Australian, open-label, multicenter, randomized, double-blind clinical trial designed to assess the efficacy of combination therapy with pegylated interferon alfa-2b and ribavirin for 48 weeks versus 24 weeks in the…
- Trial name
- NCT00255034
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Infection
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.
- Trial name
- NCT00874770
- Testing
- Daclatasvir, Peginterferon alpha-2a, ribavirin
- Where
- 14 sites in United States, France
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV
We propose to test our primary hypothesis that treatment with Peg-IFN-α-2b will result in a decrease in integrated HIV DNA in peripheral blood and tissue in chronically HIV-infected immune-reconstituted individuals (see section…
- Trial name
- NCT01935089
- Testing
- Pegylated Interferon alpha 2b
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- The Wistar Institute
Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT01708941
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Where
- 276 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, RCC
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein complex NF-kB, which controls the transfer of genetic…
- Trial name
- NCT02447887
- Testing
- Ixazomib, Pegylated IFN-alpha 2b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Hepatitis C
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2…
- Trial name
- NCT01808248
- Testing
- SOF, PEG, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
Melanoma
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
- Trial name
- NCT01986712
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- St. Luke's Hospital and Health Network, Pennsylvania
Infection
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
The goal of this clinical research study is to learn if the antiviral combination of telaprevir, pegylated Interferon Alfa 2a (PegIFN alfa-2a) and ribavirin (RBV) can prevent the virus from coming back after the liver transplant.
- Trial name
- NCT01821963
- Testing
- Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00006244
- Testing
- melphalan, recombinant interferon alfa, aldesleukin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)
The aim of this observational study is to document the efficacy and tolerability of high-dose interferon therapy in adult participants with malignant melanoma at high risk of relapse and to compare them with the survival times…
- Trial name
- NCT00749684
- Testing
- Interferon α-2b
- Volunteers
- 138 people
- Sponsor
- Merck Sharp & Dohme LLC